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Introducing CBPP
• Contagious bovine pleuropneumonia, CBPP, caused by 
Mycoplasma mycoides subsp. mycoides (Mmm) is a highly 
contagious disease that affect cattle in many countries of 
sub-Saharan Africa. 
• CBPP are among the most serious livestock diseases in 
Africa.
• Imposes an estimated minimal cost of >50,000,000 €/year 
in Africa and restricts trade
• Clinical signs include fever, coughing, respiratory distress 
and anorexia with unilateral lung lesions and pleural fluid -
acute, subacute or chronic disease
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Introducing CBPP – available vaccines ghtd
Available and OIE recommended vaccines:
• Live attenuated vaccine (mostly T1/44)
• Low efficacy 
• Short duration of protection
• Remaining virulence causing occasional post-
vaccination reactions (Willem’s reactions) at site 
of injection
• Continued attenuation: better safety profile, 
lower protection 





• Caused by Mycoplasma capricolum
subsp. capripneumoniae
• Widespread in Central and East Africa, 
Middle East and Asia
• Affects domestic goats and wild 
ruminants
• Aerosol infection
• Mortality can reach 80%
• Clinical signs similar to CBPP
• Vaccine: inactivated whole bacterin
Manso-Silván et al. 2011
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Correlate of protection?
Correlate of protection still unknown
• Vaccine candidates
• Only way to test vaccine efficacy today: challenge studies 
– costly, cumbersome and animal welfare issues
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Correlate of protection? (CBPP – none for CCPP)
T-cells
• Dedieu 2005 – IFNg secreting CD4 T-cells correlate with protection
• Sacchini et al 2011, CD4 T-cells minor role in protection
Antigen-specific serum antibodies 
• Hamsten et al., 2010, 5 candidate antigens 
• Schieck et al., 2014 - none
• VIDO, KALRO, ILRI subunit vaccine (need to be confirmed)
Mucosal antibodies: 
• Niang et al. 2006: Humoral and mucosal (BAL) levels of IgM, IgG1 and IgG2 do not correlate with severity of 
disease. All animals with high BAL levels of IgA were characterized by reduced disease severity. (Did not 
identify specific IgA targets).
• Karst et al. 1972: Intranasal vaccination using live attenuated strain showed protection
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Vaccination Challenge End of Trial,
Necropsies
-7 0 29 50(general outline)
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Vaccination Challenge End of Trial,
Necropsies













T1- NegCont saponin only
















T1- NegCont saponin only










Vaccination Challenge End of Trial,
Necropsies




BAL (in our case):
Briefly, following slaughter, the trachea together with the lungs is cut out and lavaged by introducing sterile 
PBS, into the lungs. This is followed by gentle massage of the lungs before the fluid is re-collected into a 
beaker and frozen in 50ml falcon tubes.
The BAL are diluted 1:10 with TBST/5% low fat skimmed milk and used as primary antibodies in w/b protocol
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Vaccination Challenge End of Trial,
Necropsies






CCPP and CBPP– Lacrimal fluid 
1. Protein ladder
2. BSA  (66.5kDa)
3. D0 CS011 Lacrimal fluid
4. Post vaccine Lacrimal fluid
5. Post challenge lacrimal fluid
6. Bovine BS058 D1 Lacrimal fluid
7. Bovine BS058  Lacrimal fluid D15 post challenge
Gel load:-
1. 10ul all Lacrimal fluids samples
2. 2ul Loading dye
3. 5ug BSA













Electrophoretic profile of Goat Lacrimal fluid by SDS-PAGE
SOP for lacrimal fluid 
collection established
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CCPP– Lacrimal fluid western blot
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Lacrimal IgG  reaction to Mccp lysate
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Lacrimal IgA  reaction to Mccp lysate
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CBPP – recombinant Mmm proteins





Protein ID Description MW
1 MSC -0136 Hypothetical lipoprotein 64 kDa Subunit vaccine
2 MSC -0160 Translation elongation factor Tu 75 kDa Nkando et al., 2016
3 MSC -0431 Prolipoprotein 68 kDa Subunit vaccine
4 MSC -0499 Prolipoprotein 108 kDa Subunit vaccine
5 MSC -0775 Prolipoprotein 109 kDa Subunit vaccine
6 MSC -0816  Variable surface lipoprotein 73 kDa Nkando et al., 2016
7 MSC-0079 Prolipoprotein, putative phosphonate ABC transport   69kDa Hamsten et al. 2010
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Challenge End of Trial,
Necropsies
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CBPP – recombinant Mmm proteins - BAL








SEVERE DISEASED ANIMALS 




























done on Day 0






















done on Day 0
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CBPP – recombinant Mmm proteins – IgA in BAL
1. MSC- 0136  - 64kDa
2. MSC- 0160  - 75kDa
3. MSC- 0431 - 68kDa
4. MSC- 0775 - 108kDa
5. MSC- 0499 - 109kDa
6. MSC- 0816  - 73kDa
7. MSC- 0079  - 68kDa
PROTECTED ANIMALS BAL SAMPLES 
– IgA in pooled BAL 
SEVERELY DISEASED ANIMALS 
– IgA in pooled BAL
















CBPP – recombinant Mmm proteins – IgA in BAL
1. MSC- 0136  - 64kDa
2. MSC- 0160  - 75kDa
3. MSC- 0431 - 68kDa
4. MSC- 0775 - 108kDa
5. MSC- 0499 - 109kDa
6. MSC- 0816  - 73kDa
7. MSC- 0079  - 68kDa
PROTECTED ANIMALS BAL SAMPLES – IgA in BAL 
SEVERELY DISEASED ANIMALS –IgA in BAL
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Pipette 20uL of the serum (27 dpi) on to the 
surface of the inoculated PPLO agar plate. 
Incubate at 37C. 
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Pipette 50µL of the serum (27 dpi) into the well in the inoculated












Growth inhibition assay for Mmm- agar well diffusion method.
Pipette 50µL of the serum (27 dpi) into the well in the inoculated
PPLO agar plate. Incubate at 37C for 4-7 days.
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